Natixis Advisors’s Medicines Co MDCO Stock Holding History

Natixis Advisors’s Portfolio MDCO Stock Details MDCO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-25,516	Closed	-$840K	–	1119
2018 Q1	$840K	Buy	+25,516	New	+$797K	0.01%	946

Other funds holding MDCO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Natixis Advisors's MDCO Position: Q2 2018 in Review

Natixis Advisors sold out of Medicines Co (MDCO) in Q2 2018, closing a stake of 25,516 shares — an estimated $840K sold.

Natixis Advisors first reported a position in MDCO in Q1 2018 and held it in 1 quarter. The position peaked at $840K in Q1 2018. 188 funds tracked by Wall St. Rank hold MDCO as of Q2 2018.

Natixis Advisors reported no remaining Medicines Co position as of Q2 2018 after selling out during the quarter.
Natixis Advisors sold 25,516 Medicines Co shares in Q2 2018, an estimated $840K.
Natixis Advisors first reported a position in Medicines Co in Q1 2018 and held it in 1 quarter.
Natixis Advisors's Medicines Co position peaked at $840K in Q1 2018.
188 funds tracked by Wall St. Rank held Medicines Co as of Q2 2018.

Based on Natixis Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.